Because measles-specific antibody titer after vaccination is lower than after natural infection, there is concern that vaccinated persons may gradually lose protection from measles. To examine the persistence of vaccineinduced antibody, participants of a vaccine study in 1971, with documentation of antibody 1-7 years after vaccination, were followed up in 1997-1999 to determine the presence and titer of measles antibody. Of the 56 participants (77% were 2-dose recipients), all had antibodies detected by the plaque reduction neutralization (PRN) antibody assay an average of 26-33 years after the first or second dose of measles vaccine; 92% had a PRN titer considered protective (11:120). Baseline hemagglutination inhibition antibody titer in 1971 strongly predicted follow-up PRN antibody titer ( ). Persistence of antibody in these primarily 2-dose recipients P ! .001 supports the current elimination strategy to achieve and sustain high population immunity with a 2-dose schedule.
To prevent reestablishment of indigenous measles transmission in the United States, a high level of protection against measles in the population must be sustained [1] [2] [3] . A potential obstacle to sustaining this high level is waning of vaccine-induced protection over time, or secondary vaccine failure [4] [5] [6] [7] . Because measles-specific antibody titer after vaccination is lower than after natural infection, there is concern that vaccinated persons may gradually lose protection from measles. Secondary vaccine failure, in contrast to primary vaccine failure (no protection after vaccination), is a concern because of the potential insidious challenge to measles elimination. For instance, if vaccine-induced immunity waned to nonprotective levels in a high proportion of vaccinated adults, the level of population protection might decline to allow recurrence of endemic disease. By means of statistical modeling, Mossong et al. [8] predicted waning of vaccine-induced immunity 25 years after immunization.
Isolated cases of measles in persons with documented seroconversion after vaccination have been reported [4, 6, 7] . These secondary vaccine failures among adults in the United States, Canada, and China are of concern and provide evidence that vaccine-induced protection may wane. However, the magnitude of the problem seems small. The number of reported measles cases in the United States has been at record low levels since 1996, and the number of reported cases in adults has been very small (32 cases in persons у20 years of age in 1999). Though a small number, measles cases in vaccinated adults (22% of cases in adults) suggest that waning vaccine-induced protection may explain some vaccine failures [9, 10] .
Although waning vaccine-induced immunity does occur, population-based prevalence is not known in the United States. Little is known about the levels of measles protection among adults. The third National Health and Nutrition Examination Survey (NHANES III), conducted during [1988] [1989] [1990] [1991] [1992] [1993] [1994] , found that 93% of participants aged у6 years had measles antibody [11] . This finding suggests that measles immunity in the United States is high. However, measles vaccination history was not available for NHANES participants and could not be linked with seroprevalence results. Even if vaccina-tion status were known, we still could not distinguish between primary and secondary vaccine failure without knowing the initial response to vaccination. The present study was undertaken to estimate the prevalence of measles antibody among a population of adults with documentation of vaccination an average of 26-33 years before and whose initial documentation of measles antibody titers occurred in 1971 after initial vaccination [12] . By studying blood drawn several decades after vaccination and documentation of initial measles antibody, it should be possible to estimate whether measles antibody persists in this population of vaccinated adults and to examine whether loss of antibody over time results in susceptibility to measles in the United States when continued antigenic stimulation is unlikely because the risk of measles exposure is low.
METHODS

Serological Study
In the initial 1971 study in Cincinnati, Ohio, measles serological status was examined for 182 children before and after vaccination with a live measles virus vaccine [12] . Of the 182 children, 131 were initially vaccinated at !1 year of age and 51 were vaccinated at у1 year of age. Of the 182 children, 97 received a live attenuated measles vaccine (74 with immune globulin and 23 with no record of receipt of immune globulin) and 85 received a live, further attenuated measles vaccine. About one-half were revaccinated between 19 months and 13 years of age with a live, further attenuated vaccine (Moraten vaccine strain, the only strain now currently in use in the United States). Revaccination was 1-7 years after the first dose of measles vaccine. All of the study participants had a documented measles antibody titer after the first or second dose of vaccination [12] . Antibody was measured by the standard hemagglutination inhibition (HI) assay, an assay no longer commonly used. Participants who had received у2 doses were revaccinated during the 1971 study because their first dose was usually administered at !1 year of age. In 1965, the recommended age at vaccination was increased from 9 months to 12 months [3] . At that time, the Advisory Committee on Immunization Practices recommended revaccination of children vaccinated at !1 year of age [3] . In addition, children in the 1971 study were also revaccinated if their HI antibody titer was р1:40.
1997-1999 Follow-Up Study
Study design and population. In the follow-up study, we recruited as many of the participants from the 1971 study population as possible. Many of the patients still resided in the Cincinnati area. Participants were found through pediatric medical records, local phone books, and Web-based directories for the United States. The study protocol was reviewed and approved by the Institutional Review Boards of the Children's Hospital, Cincinnati, and of the Centers for Disease Control and Prevention (CDC).
Collection of information and blood. Participants in the 1971 study who agreed to participate in the follow-up study were interviewed and had blood drawn in the pediatrician's office or a medical laboratory. Arrangements were made for a representative from a local chapter of the Visiting Nurses' Association to complete the interview and draw blood from participants who lived outside the Cincinnati area. Participants were interviewed to obtain demographic information and history of measles exposure, disease, and vaccination in the intervening years between 1971 and 1999. Initial vaccination history and antibody titers were abstracted from the original office medical records from the 1971 study. In the follow-up study, 1 blood specimen was collected for each participant between 1997 and 1999. Sera were frozen and shipped to the CDC for analysis.
Participants in the 1997-1999 follow-up study were classified into 3 groups on the basis of type of vaccine received, number of doses received, and timing of blood drawn at the initial study in 1971. In group A, participants received a single dose of either a live attenuated vaccine strain (Edmonston B) with immune globulin or a live, further attenuated vaccine (Schwartz or Moraten) without immune globulin before the 1971 study. Blood for HI antibody testing was collected in 1971, on average, 4 years after initial vaccination (range, 2-8 years). In group B, participants received a first dose of a live, attenuated vaccine strain with immune globulin, a live, further attenuated vaccine without immune globulin, or an inactivated vaccine (Edmonston B) before the 1971 study and a second dose of a live, further attenuated vaccine (Moraten only) during the 1971 study. For this group, blood for HI antibody testing was collected in 1971, an average of 6 years (range, 2-8 years) after the first dose of vaccine and immediately before the second dose. Some children returned to have a second blood sample drawn 2-11 weeks after revaccination. In group C, participants received a first dose of a live, attenuated vaccine or an inactivated vaccine as in group B, the second dose was either the Moraten vaccine or an inactivated vaccine, and the third dose was a Moraten vaccine. Blood for HI testing was collected in 1971, an average of 7 years (range, 6-7 years) after the first dose of vaccine and immediately before the second or third dose if the second dose was an inactivated vaccine. For the purposes of the follow-up study, for all 3 groups, only the HI titer from blood collected after the first dose of measles vaccination and before revaccination during the 1971 study for groups B and C was defined as the baseline HI titer.
Laboratory Methods
Two serological assays were performed at the CDC for each blood specimen from a participant to detect measles antibody. First, the plaque reduction neutralization (PRN) assay was done, which is considered the "gold standard" [13] . This test is 12%-17% more sensitive than the EIA and is considered to be 60-fold more sensitive than the HI assay used in the 1971 study [14] [15] [16] [17] . Because the EIA is practical and widely used, serum samples were also tested by EIA. We were not able also to examine follow-up serum samples for HI antibody because the HI assay is no longer widely available.
To detect PRN antibody, serum was serially diluted beginning at 1:8 [13] . The PRN antibody titer was reported as the dilution of serum that reduced plaques by 50%. Adults with an antibody titer of у1:120 were considered protected from measles because a titer at that level was found in several outbreaks to be associated with protection against classical measles [16, 18, 19] . Analysis of risk factors for measles susceptibility was limited only to PRN antibody results, because a serological correlate of protection had been identified for this assay.
The EIA detected measles-specific IgG antibody to recombinant measles virus nucleoprotein [14] . Serum was defined as positive for antibody by an optical density reading of P Ϫ N у and , where P was the average optical density of 0.09 P/N у 3.00 duplicate positive wells and N was the average value of duplicate negative wells.
Statistical Analysis
Because the sample size was relatively small for estimating prevalence and risk factors for measles susceptibility, exact statistics were used. StatXact-3 and LogXact software were used for univariate, bivariate, and multivariate analyses [20, 21] . We estimated the 95% confidence interval of the prevalence of antibody using the binomial distribution. The Fisher-FreemanHalton test was performed to detect differences between proportions, and the Kruskal-Wallis test was used to examine differences in the overall distribution of a continuous variable in a population [20] . Although this is a prospective study, the distribution of a continuous variable (exposure variable) in a bivariate analysis could be examined relative to the PRN titer (outcome variable) with this sample size only by use of exact statistics. Thus, instead of examining the difference in the PRN antibody titer between exposure populations, we examined the distribution of the exposure variable by the outcome variable. To conduct unconditional logistic regression, the unstratified version of logistic regression in LogXact was attempted but was unsuccessful because of very sparse data [21] . All antibody titers were reported by computing the reciprocal of the titer.
RESULTS
Study population.
Of the 182 patients in the initial 1971 cohort, we were able to locate the charts of 174. Of these, 64 consented to participate in the follow-up study, were interviewed, and had blood drawn. Of the 64 participants, 4 were excluded because they did not have a vaccination history or were found later to have had a history of measles exposure or disease. An additional 4 persons were excluded because they had received a second or third dose of measles vaccine within 10 years of the 1997-1999 follow-up study. None of the remaining 56 participants reported having had measles or a known exposure to measles during the follow-up period after the 1971 study.
The 56 study participants in the 1997-1999 follow-up study were slightly older and were more likely to be female than were nonparticipants ( ) (table 1) . In addition, participants P ! .01 were slightly older than nonparticipants at the first and second dose of measles vaccination ( and , respectively). P p .04 P ! .01 There were no other statistically significant differences between study participants and nonparticipants by vaccine group (type and number of vaccine doses), years since vaccination, baseline HI antibody titer, the age at HI testing, and years since HI titer was determined.
Study participants were born between 1957 and 1969, the early part of the vaccine era. Their mean age at the 1997-1999 follow-up study was 34 years (range, 29-40 years; table 1). Seventy-one percent of participants were female. Most participants (77%) had received 2 doses of measles vaccine and were classified as group B. Of the 43 participants in group B, 42 had received a first dose of the live, attenuated vaccine with immune globulin or a live, further attenuated vaccine without immune globulin (table 2) . The remaining participant in group B received a first dose of an inactivated vaccine before revaccination with the live vaccine. Ten participants in group A received a single dose of a live vaccine, whereas 2 participants in group C received 3 doses of a live vaccine. The remaining participant in group C received 2 doses of an inactivated vaccine before a live vaccine. Overall, the mean age at the first dose was 19 months, at the second dose was 8 years, and at the third dose was 17 years (table 1) . Participants in group C with 3 doses had received the third dose in 1971, 1983, or 1987 .
Depending on the number of doses of measles vaccine received, the mean number of years between the last dose of measles vaccine and the 1997-1999 follow-up study was 18-33 years (table 1) . Most participants (77%) had received 2 doses of measles vaccine. The second dose was received in 1971, a mean of 26 years before collection of the follow-up blood sample; most 2-dose recipients (75%) had received the second dose of vaccine 26-33 years previously. Eighteen percent of participants received only a single dose and were vaccinated a mean of 32 years before the follow-up blood sample was obtained; the single dose of vaccine was received between 28 and 36 years previously. The third dose was received a mean of 18 years (11, 16, and 27 years) before collection of follow-up blood.
All participants had documentation of a baseline HI antibody titer in 1971 after initial vaccination. Mean age at collection of the baseline blood sample for HI assay was 7 years (table 1) . Thirty-three participants (59%) had HI antibody reciprocal titers between 5 and 20; the remaining 23 (41%) had titers of 40 (12 participants) or 140 (11 participants). Only 15 (27%) of the 56 participants also had a second titer measured 2 to 8 weeks after the second dose of vaccine. Of the 15, 11 (73%) had a titer of у40 after the second dose, whereas 4 (27%) had a titer of between 5 and 20. The baseline HI titer was obtained a mean of 27 years before the 1997-1999 follow-up blood sample was obtained.
Prevalence of vaccine-induced antibody. The prevalence of measles antibody was very high a mean of 26-33 years after 1 or more doses of measles vaccine. All 56 participants had PRN antibody detected (PRN antibody titer of у1:8), and nearly all (92%) had a positive EIA antibody test result. Fiftyone of the participants had a reciprocal PRN titer of 1120; only 5 (prevalence, 9%; 95% confidence interval, 3%-20%) had a PRN titer not considered to be protective (р120) (table 2). To identify risk factors for measles susceptibility, we examined the study participants' characteristics relative to a low reciprocal PRN titer of р120 and a higher PRN titer of 1120. We found slightly more women than men with a PRN titer of р120, but the difference was not statistically significant (table  2) . Although more group B participants and participants with baseline HI titers of 5-20 had PRN antibody titers of р120 than did other groups or those with higher baseline HI titers, the differences were not statistically significant. In addition, the distribution of continuous variables (i.e., age at and years since vaccination and age at and years since baseline HI titer determination) by PRN antibody was not statistically different, although the mean age at first and second dose was younger among participants with a PRN antibody titer of р120 than among those with a higher antibody titer. We further examined the relationship between the baseline HI antibody titer and the follow-up PRN antibody titer and found a strong, positive relationship of grouped HI antibody titers (i.e., [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 40 , and 140) and geometric mean PRN antibody titer ( ) ( figure 1) . The higher the baseline HI P ! .001 titer, the higher the mean PRN titer of the follow-up serum samples. When we further classified participants into 3 groups on the basis of their PRN antibody titer to distinguish very high antibody titer (1900) from low (р120) and moderate (121-900) titers, we found baseline HI titers to predict PRN titers and also to be statistically significant ( ) (table 3) . P ! .01 Comparing participant characteristics relative to the 3-level classification of PRN titers showed no other statistically significant relationships by age at follow-up study, sex, age and time since vaccination, and age and time since baseline HI titer determination. Categorical analysis of age at vaccination and years since first and second of measles vaccine did not show statistically significant results (table 3) . Although relatively more recipients with a first dose at !12 months of age and those vaccinated 126 or 130 years after the second dose had a PRN titer of р120 than those vaccinated older or sooner, these proportions were not statistically different.
DISCUSSION
This is the first study in the United States to examine persistence of vaccine-induced antibody an average of 25 years after vaccination [22] [23] [24] [25] . All 56 participants had detectable PRN antibody and nearly all (92%) had PRN titers considered to be protective (PRN antibody titer of 11:120), despite no known exposure to the wild measles virus or measles disease after vaccination. Measles was not reported in any of the 56 vaccinated participants, although measles was circulating at low levels in the United States (0.04 cases/100,000 population in 1999 to 23 cases/100,000 population in 1970) and very low levels in Cincinnati (0-4 cases annually since 1985, the first year of national electronic reporting).
If the PRN assay is 60-fold more sensitive than the HI assay used in 1971 [17] , we estimate that a decline in antibody titer may have occurred over time in some study participants. The lowest detectable antibody titer by HI is 1:5. This titer translates to a PRN titer of 1:300. Of the 9 participants with a PRN titer of !1:300 at follow-up, all had baseline HI titers between 1:5 and 1:40 in 1971; most (7) had titers between 1:5 and 1:10. Thus, in participants with the lowest titers in 1971, antibody may have waned to levels not considered protective. However, waning vaccine-induced antibody resulting in no likely protection is small. We would expect vaccine-induced antibody to wane some, as we would expect antibody induced by disease to wane [22] [23] [24] . However, waning antibody does not necessarily mean that protection from measles also has waned, because cellular immunity may persist, resulting in a vigorous secondary antibody response upon exposure to measles virus [26, 27] . Moreover, a recent study suggests that one-half of persons with a single dose of vaccine resulting in a PRN titer of !125 are protected from measles, although this study examined measles up to 11 years after vaccination [18] . The interaction of humoral and cellular immunity needs to be evaluated to understand why low antibody titers persist even when a person has cellular immunity and is found to be protected from measles.
Presence of low vaccine-induced antibody (PRN antibody titer of р120) after documentation of adequate HI antibody following initial vaccination suggests that measles antibody for a small number of participants may have decreased to titers considered nonprotective. The 9% prevalence of low PRN antibody titer found in the present study is consistent with the secondary vaccine failure rate found in Canada (5%) [6] and with a meta-analysis of 9 studies conducted by Anders et al. [28] that found a secondary vaccine failure rate of 0% to 6%, which includes the Canadian study. Anders et al. [28] pooled data from studies conducted in North America, Taiwan, and Japan. These studies include cohorts of healthy persons who received a live measles-containing vaccine, had a blood test demonstrating serological immunity after measles vaccination, were exposed to measles, and developed disease at least 21 days after vaccination, as judged on the basis of clinical or serological data. These investigators found a 6% (95% confidence interval, 4%-8%) secondary vaccine failure rate for 3 studies (2 of which were conducted outside the United States) with a total of 572 participants who had received a live measles vaccine. The age at vaccination was unknown in 2 of the 3 studies; 12 months was the reported age in the other study. Pooled results for the remaining 6 studies (5 which were conducted in the United States) found an even rarer secondary vaccine failure rate (0; 95% confidence interval, 0-0.15%) among 12000 participants. For half of these studies, age at vaccination was available and ranged from 48 to 56 months, which is older than ages in the present study. The number of years since vaccination was not available for any of the studies and was not reported in the meta-analysis, in contrast to the present study, which estimates prevalence of antibody an average of 26-33 years after vaccination. Before the present study, the longest follow-up study of persistence of measles antibody after vaccination and disease was conducted by Krugman et al. [22] [23] [24] . In follow-up studies that examined antibody to measles as much as 16 years after wild virus infection or vaccination, no evidence was found that protection against measles had waned to nonprotective levels from serological results after revaccination, although antibody after both natural infection (47 participants) or vaccination (70 participants) decreased over time. Krugman found typical booster responses after revaccination among persons with negative results of HI assay, suggesting persistence of immunologic memory. In addition, among 16 participants with low HI antibody titers (1:2-1:4) 6-15 years after vaccination, PRN antibody titers were higher (1:4-1:46), suggesting that actual titers may be higher than measured by the HI assay. These results suggest that protection does not seem to wane and also document a higher sensitivity of the PRN assay than the HI assay in detecting measles antibody.
A potential limitation of our study is the low participation rate, which may be expected in a follow-up study nearly 3 decades after the initial study. Although participants were slightly older, more likely to be female, and received the first or second dose of measles vaccine at a slightly older age than nonparticipants, the distribution of baseline HI titer was similar among participants and nonparticipants. This is an important finding, because the baseline HI titer was the most important predictor of the later PRN titer, the basic measurement of measles antibody in this study. All 5 participants with low PRN antibody considered susceptible had low (10 or 20) baseline HI titers nearly 3 decades before; all but 1 had 2 doses of measles vaccine. Another potential limitation is that blood for most participants (78%) was obtained before revaccination and not after. These HI titers do not reflect the last titer after vaccination in 1971, which would include boosting of antibody after revaccination. However, several studies suggest that while boosting does occur, it is only transient [25, 29, 30] . The longest prospective cohort study of revaccinated children aged 4-6 years found boosting to last just 6 months after revaccination [30] . Antibody titers increased after vaccination for all participants but declined to prevaccination levels for nearly all participants at 6 months. Finally, because only 56 participants were examined, we did not have sufficient power to detect small differences in age at vaccination, years since vaccination, age at baseline HI titer determination, or years since the baseline HI titer was determined. Our statistical power was only 2% to detect differences of 145% between the group with low PRN antibody titer (р120) and the group with higher PRN antibody titer. Both young age (!12 months) at vaccination and many years since vaccination have been found to predict low seroprevalence and seroconversion rates [31] . In addition, higher attack rates during outbreaks have been found among children vaccinated at !12 months of age and in the more distant past [31] .
This provider-based study does demonstrate that data in the offices of physicians in private practice can be a valuable resource in answering medical questions of national importance, such as the degree of persistence of vaccine-induced measles antibody. Although the study population included adults who were vaccinated with 1, 2, or 3 doses of measles vaccine many years before, our results primarily reflect persistence of antibody among 2-dose recipients, among whom one-half had received the first dose at age !1 year. Our findings suggest that persons who have received either a single dose or 2 doses of vaccine a mean of 26-33 years before may still have detectable neutralizing antibody, and nearly all may still have titers considered to be protective (11:120) . The persistence of antibody in this diverse group of vaccine recipients supports the current elimination strategy to achieve high population immunity with 2 doses of measles vaccine.
